ROIV
Roivant Sciences Ltd.
Stock
$35.72+0.22 (+0.62%)Close Oct 2, 2026
Income statement
| Line | Last 12 months | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|---|
| Revenue | $7.5M | $8.3M | $29M | $33M | $32M | $55M | $24M |
| R&D | $731M | $682M | $550M | $440M | $454M | $483M | $237M |
| SG&A | — | — | — | $687M | $601M | $775M | — |
| Operating income | −$596M | −$515M | −$1.0B | $4.5B | −$907M | −$1.4B | −$1.1B |
| Non-operating income | $306M | $250M | $322M | $71M | $22M | $428M | $172M |
| Pretax income | −$290M | −$265M | −$682M | $4.6B | −$885M | −$924M | −$899M |
| Taxes | −$24M | $35M | −$510M | $219M | $124M | −$78M | −$89M |
| Net income | −$266M | −$300M | −$172M | $4.3B | −$1.0B | −$845M | −$809M |
| Diluted EPS | −$0.47 | −$0.54 | −$0.24 | $5.23 | −$1.42 | −$1.26 | −$1.28 |
| Diluted shares | — | 693.9M | 725.4M | 831.0M | 712.8M | 669.8M | 630.0M |
| Revenue growth | — | −71.6% | −11.2% | +3.8% | −43.0% | +132.3% | — |
| Operating margin | −7,914.8% | −6,235.7% | −3,453.3% | 13,746.9% | −2,875.9% | −2,444.8% | −4,500.5% |
| Net margin | −3,535.0% | −3,629.2% | −592.0% | 13,294.2% | −3,200.2% | −1,528.9% | −3,400.9% |